Literature summary for 2.4.1.155 extracted from

Yamamoto, E.; Ino, K.; Miyoshi, E.; Shibata, K.; Takahashi, N.; Kajiyama, H.; Nawa, A.; Nomura, S.; Nagasaka, T.; Kikkawa, F.
Expression of N-acetylglucosaminyltransferase V in endometrial cancer correlates with poor prognosis (2007), Br. J. Cancer, 97, 1538-1544.

Search for more literature for 2.4.1.155

Application

Application	Comment	Organism
medicine	high GnT-V expression is correlated with impaired clinical outcome in endometrial cancer patients, GnT-V is an independent prognostic factor for progression-free survival	Homo sapiens

Molecular Weight [Da]

Molecular Weight [Da]	Molecular Weight Maximum [Da]	Comment	Organism
110000	-	determined by Western blot analysis	Homo sapiens

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
UDP-N-acetyl-D-glucosamine + 6-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R	Homo sapiens	-	UDP + 6-(2,6-bis[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R	-	?

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Posttranslational Modification

Posttranslational Modification	Comment	Organism
glycoprotein	-	Homo sapiens

Source Tissue

Source Tissue	Comment	Organism	Textmining
choriocarcinoma cell	-	Homo sapiens	-
endometrioid carcinoma cell	endometrial endometrioid adenocarcinoma cell	Homo sapiens	-
JAR cell	-	Homo sapiens	-
uterine smooth muscle cell line	UtSMC, CC-2562	Homo sapiens	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
UDP-N-acetyl-D-glucosamine + 6-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R	-	Homo sapiens	UDP + 6-(2,6-bis[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R	-	?

Synonyms

Synonyms	Comment	Organism
GnT-V	-	Homo sapiens
N-acetylglucosaminyltransferase V	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)